HSPA5 and Parkinson disease: Such observation contrasts with previous studies that situated BiP as a neuroprotectant factor in PD acting through mechanisms that involve UPR pathways [27], but these studies were conducted in PD models based on the formation of α-synuclein aggregates, which is not the case with 6-OHDA lesions.